Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB9 | P28065 | 12/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12472519 | 0.85 | PSMB9 (0.35) | PSMB9PSMB8ALOX15HSD17B10KDM4E | |
| SCHEMBL15509451 | 0.83 | CTSB (0.41) | PSMB9PSMB8CTSB | |
| SCHEMBL8249221 | 0.83 | CTSB (0.41) | PSMB9PSMB8CTSB | |
| SCHEMBL7914476 | 0.83 | CTSB (0.41) | PSMB9PSMB8CTSB | |
| SCHEMBL15509452 | 0.83 | CTSB (0.41) | PSMB9PSMB8CTSB | |
| SCHEMBL15509453 | 0.83 | CTSB (0.41) | PSMB9PSMB8CTSB | |
| SCHEMBL15849570 | 0.79 | PSMB9 (0.36) | PSMB9PSMB8MAPTPSMB5 | |
| SCHEMBL12468417 | 0.79 | PSMB9 (0.36) | PSMB9PSMB8MAPTPSMB5 | |
| SCHEMBL12467641 | 0.79 | PSMB9 (0.36) | PSMB9PSMB8MAPTPSMB5 | |
| SCHEMBL12468425 | 0.76 | PSMB9 (0.34) | PSMB9PSMB8SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SERPINB1, CTSC, HPN | PSMB9 434/4885PSMB8 271/4885ALOX15 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.